Other substances

Bortezomib

A proteasome inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

3
 Supporting references
0
 Contradictory references
4
 AI-suggested references
0
 Clinical trials

General information

Bortezomib is a dipeptide boronic acid analogue. It displays antineoplastic activity. Bortezomib acts as a reversible proteasome inhibitor (NCIt).

Bortezomib on DrugBank
Bortezomib on PubMed
Bortezomib on Wikipedia

Marketed as

BORTEZOMIB; VELCADE

 

Structure image - Bortezomib

B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
in silico Feb/22/2020
Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19
Preprint 		VERO E6 cell cultures Apr/09/2020
Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis
Small molecule In silico Screening 		in silico (protein-protein interaction network analysis) 2.31

Computationally predicted to be efficacious in COVID-19 treatment based on protein-protein interaction network analysis.

 Mar/12/2021

AI-suggested references

Link Publication date
[Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.]
Dec/03/2020
Successful second outpatient autologous hematopoietic cell transplant for relapsed POEMS syndrome in a patient with coexisting HIV, HBV and syphilis infections during the COVID-19 pandemic.
Dec/02/2021
Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2
May/20/2020
Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets.
Sep/08/2021
Export (.csv)